We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+10.17%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$15.4B
AUM Growth
+$2.08B
Cap. Flow
+$1.36B
Cap. Flow %
8.86%
Top 10 Hldgs %
54.82%
Holding
115
New
20
Increased
35
Reduced
31
Closed
11

Top Buys

Rank Stock Value
1
APC
Anadarko Petroleum
APC
+$702M
2
CELG
Celgene Corp
CELG
+$666M
3
WCG
Wellcare Health Plans, Inc.
WCG
+$459M
4
RHT
Red Hat Inc
RHT
+$333M
5
AGN
Allergan plc
AGN
+$138M

Top Sells

Rank Stock Value
1
TRU icon
TransUnion
TRU
+$181M
2
GOOG icon
Alphabet (Google) Class C
GOOG
+$173M
3
META icon
Meta Platforms (Facebook)
META
+$169M
4
BKNG icon
Booking.com
BKNG
+$157M
5
GG
Goldcorp Inc
GG
+$148M

Sector Composition

Rank Sector Weight
1 Healthcare 33.27%
2 Technology 17.66%
3 Communication Services 13.38%
4 Industrials 6.69%
5 Consumer Discretionary 4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRFS
51
Grifois
GRFS
$5.36B
$65M 0.42%
3,080,083
+153,731
+5% +$2.93M
EXEL icon
52
Exelixis
EXEL
$13.3B
$64.1M 0.42%
3,000,000
– –
GBT
53
DELISTED
Global Blood Therapeutics, Inc.
GBT
$59.2M 0.38%
1,125,000
-375,000
-25% -$21.6M
LBTYA icon
54
Liberty Global Class A
LBTYA
$3.62B
$56.2M 0.37%
2,083,977
-1,865,576
-47% -$49.2M
ARWR icon
55
Arrowhead Research
ARWR
$11.9B
$53M 0.34%
2,000,000
+79,391
+4% +$1.74M
FATE icon
56
Fate Therapeutics
FATE
$286M
$50.8M 0.33%
2,500,000
– –
RDUS
57
DELISTED
Radius Health, Inc.
RDUS
$49.8M 0.32%
2,043,149
– –
CVS icon
58
CVS Health
CVS
$133B
$44.8M 0.29%
822,500
+197,500
+32% +$10.6M
FOX icon
59
Fox Class B
FOX
$21.8B
$43.2M 0.28%
1,182,500
-1,624,931
-58% -$59M
NXPI icon
60
NXP Semiconductors
NXPI
$57.8B
$42M 0.27%
430,000
-105,000
-20% -$10.2M
ZYME icon
61
Zymeworks
ZYME
$1.61B
$38.6M 0.25%
1,756,470
+181,470
+12% +$3.33M
FDC
62
DELISTED
First Data Corporation
FDC
$38.6M 0.25%
+1,425,000
New +$37.1M
PGNX
63
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$34.2M 0.22%
5,543,386
+1,342,566
+32% +$6.47M
RC
64
Ready Capital
RC
$258M
$33.4M 0.22%
2,243,239
– –
TMUS icon
65
T-Mobile US
TMUS
$185B
$31.6M 0.21%
+425,780
New +$31.6M
FOXA icon
66
Fox Class A
FOXA
$24.5B
$30.6M 0.2%
836,400
+127,180
+18% +$4.67M
BPL
67
DELISTED
Buckeye Partners, L.P.
BPL
$29.6M 0.19%
+719,857
New +$27.2M
PTCT icon
68
PTC Therapeutics
PTCT
$5.68B
$27M 0.18%
600,000
-100,000
-14% -$3.95M
CRSP icon
69
CRISPR Therapeutics
CRSP
$4.73B
$23.6M 0.15%
500,000
-225,000
-31% -$8.99M
QTNT
70
DELISTED
Quotient Limited Ordinary Shares
QTNT
$23.4M 0.15%
+62,500
New +$22.3M
CDXS icon
71
Codexis
CDXS
$151M
$23M 0.15%
1,250,000
– –
STML
72
DELISTED
Stemline Therapeutics, Inc.
STML
$23M 0.15%
1,500,000
-500,000
-25% -$7.23M
SINA
73
DELISTED
Sina Corp
SINA
$22M 0.14%
510,000
-140,000
-22% -$7.34M
ZEAL
74
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$21.6M 0.14%
1,000,000
+51,300
+5% +$1.04M
NVTA
75
DELISTED
Invitae Corporation
NVTA
$21.1M 0.14%
900,000
+600,000
+200% +$12.8M
1 2
3
4 5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Farallon Capital Management held 115 positions worth $15.4B, up 16% from $13.3B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Farallon Capital Management deployed $1.36B of net new capital in Q2 2019, opening 20 new positions and adding to 35 existing holdings. Its largest new stake was Anadarko Petroleum: 10,465,000 shares worth $738M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 27% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was TransUnion, an estimated $181M trimmed.

  • Farallon Capital Management's largest Q2 2019 buy was Anadarko Petroleum: 10,465,000 shares worth $738M.
  • Farallon Capital Management added most to Celgene Corp in Q2 2019, an estimated $666M increase.
  • Farallon Capital Management's biggest Q2 2019 reduction was TransUnion, cutting an estimated $181M.
  • Farallon Capital Management fully exited Goldcorp Inc in Q2 2019, selling an estimated $148M.
  • Farallon Capital Management's ten largest holdings make up 55% of its $15.4B portfolio in Q2 2019.
  • Farallon Capital Management opened 20 new positions and closed 11 in Q2 2019.
  • Farallon Capital Management's portfolio value rose 16% quarter-over-quarter to $15.4B.

Based on Farallon Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.